ASH 2019 | BPDCN common in the setting of prior/concomitant hemoncs
Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX, discusses the characteristics and outcomes of blastic plasmacytoid dendritic cell neoplasm (BPDCN) patients in the modern era from almost a decade of follow-up. He highlights how BPDCN commonly presents in the setting of prior or concomitant hematologic malignancies, and that treatment on clinical trials has now become the most commonly employed therapeutic strategy for BPDCN. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up